STOCK TITAN
  1. Home
  2. News
  3. EVTCY

EVTCY - EVTCY STOCK NEWS

Welcome to our dedicated page for EVTCY news (Ticker: EVTCY), a resource for investors and traders seeking the latest updates and insights on EVTCY stock.

Evotec SE (symbol: EVTCY) is a life science company based in Hamburg, Germany, with a unique business model focused on discovering and developing highly effective therapeutics. The company operates globally with over 5,000 employees and has strategic activities in neurology, oncology, metabolic, and infectious diseases. Evotec's multimodality platform combines innovative technologies, data, and science to create a world-leading co-owned pipeline for innovative therapeutics. The company collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders to deliver cutting-edge pharmaceutical products.

News

Evotec SE Reports First Half-Year 2023 Results on 29 August 2023

Rhea-AI Summary
Evotec SE to announce financial results for first half-year of 2023 on August 29, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News

Evotec Provides Update on Financial Impact of Cyber-Attack

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Evotec and Bristol Myers Squibb Enter Licence Agreement within Neuroscience Partnership

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
News

Just - Evotec Biologics Awarded Second Contract from U.S. Department of Defense Under Accelerated Antibodies Program

Rhea-AI Summary
Evotec SE's subsidiary, Just - Evotec Biologics, has been awarded a contract worth up to $74 million by the U.S. Department of Defense (DOD) to develop monoclonal antibody-based drug prototypes for orthopoxviruses. The contract includes antibody discovery, development, and clinical trial services. Evotec will leverage its technology platform, J.DESIGN, and its pre-clinical and clinical biologics development capabilities to accelerate the development of safe and efficacious medical countermeasures.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Evotec Receives Milestone Payment for First Patient Dosed in Phase I Study of Bayer Kidney Disease Programme

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Evotec SE Annual General Meeting 2023 Approves All Proposed Agenda Items

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Evotec Presents Sustainability Strategy

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Evotec Receives Grant from Open Philanthropy for Discovery of RNA-Targeting Henipavirus Therapeutics

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Evotec publishes Annual Report 2022 and Quarterly Statement for Q1 2023

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
News

Just - Evotec Biologics Enters Strategic Biosimilars Partnership with Sandoz

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership

FAQ

Where is Evotec SE based?

Evotec SE is based in Hamburg, Germany.

What is Evotec SE's business model?

Evotec SE focuses on discovering and developing highly effective therapeutics.

How many employees does Evotec SE have?

Evotec SE operates globally with over 5,000 employees.

What are Evotec SE's strategic activities?

Evotec SE has strategic activities in neurology, oncology, metabolic, and infectious diseases.

Who does Evotec SE collaborate with?

Evotec SE collaborates with top pharmaceutical companies, biotech firms, academic institutions, and other healthcare stakeholders.

Stock EVTCY logo
EVTCY

OTC:EVTCY

EVTCY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

EVTCY Stock Data

254.93M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Germany
Hamburg